Document Detail

Evaluation of safety and efficacy of prolonged suppressive therapy of genital herpes with valacyclovir.
MedLine Citation:
PMID:  19644189     Owner:  NLM     Status:  MEDLINE    
The aim of study was to determine the effectiveness, safety and side effects of suppressive therapy (valacyclovir) for relapsing genital herpes virus infections. Patients with HSV were divided into three groups: the first group was composed of 82 patients (45 males and 37 females) who received 500 mg of valacyclovir single dose daily during 6 months. The second group was composed of 52 patients (29 males and 23 females) who received 500 mg of valacyclovir single dose daily during 12 months. The third group was composed of 152 patients (87 males and 65 females), who received 500 mg of valacyclovir single dose daily during 24 months. Control group was composed of 60 patients (32 males and 28 females) who were treated with topical antiseptics. Several side effects such as headache (in 12% of patients), sickness (6%) and diarrhoea (3%) have been seen with the same frequency in patients and control group. Frequency of more serious complications, such as HBV infections, leukopenia, strong headaches was very low (0.2%). Other haematological and biochemical parameters were normal. Genital herpes reoccurrence was demonstrated only in 3% of patients. Relapse of genital herpes during suppressive therapy was seen in 9 % of patients. In control groups the same measure was 86% in patients. It is concluded, that continuous suppressive therapy of HSV infections with valacyclovir is safe and effective treatment, which strongly prevents reoccurrence or transmissions of HSV infections to sexual partners. Suppressive therapy few weeks before the expected delivery will decrease: the risk of relapse and need for cesarean section.
N Durglishvili; D Shishniashvili; V Kvirkvelia
Related Documents :
1988829 - A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus...
8059779 - Niaid mycoses study group multicenter trial of oral itraconazole therapy for invasive a...
6360739 - Tromantadine hydrochloride in the treatment of herpes simplex. results of a double-blin...
8186139 - A double-blind, randomized, stratified controlled study of the treatment of tinea imbri...
9270509 - A randomized trial to assess once-daily topical treatment of tinea corporis with butena...
9470329 - Maintenance therapy with itraconazole after treatment of cryptococcal meningitis in the...
17012989 - Carbon dioxide laser vaporization of condyloma acuminata.
22616799 - The relationships between preoperative sexual desire and quality of life following radi...
12887289 - A survey of pituitary incidentaloma in japan.
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Georgian medical news     Volume:  -     ISSN:  1512-0112     ISO Abbreviation:  Georgian Med News     Publication Date:    2009 Jul-Aug
Date Detail:
Created Date:  2009-07-31     Completed Date:  2010-01-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101218222     Medline TA:  Georgian Med News     Country:  Georgia (Republic)    
Other Details:
Languages:  eng     Pagination:  47-9     Citation Subset:  IM    
Institute of Dermatology and Venereology, Department of Viral Pathology, Tbilisi, Georgia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acyclovir / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Antiviral Agents / administration & dosage,  adverse effects,  therapeutic use*
Herpes Genitalis / drug therapy*
Recurrence / prevention & control
Treatment Outcome
Valine / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Antiviral Agents; 124832-27-5/valacyclovir; 59277-89-3/Acyclovir; 7004-03-7/Valine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Anatomo-physiologic and morpho-functional characteristics of juvenile football players in georgia.
Next Document:  Some aspects of the clinical use of lercamen (lercadipine).